Pular para o conteúdo principal
Ranking Invest

CALT - Calliditas Therapeutics AB (publ)

Segmento: HealthcareCalliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Análise Ranking Invest

Valuation estimado
-$ 1.72 Bi
Último Balanço Atualizado: 2T2024

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 106.79 Mi

Dívida Líquida

$ 210.99 Mi

L4T

-$ 480.36 Mi

MM4T

-38.25%

Indicadores Básicos

ROE

-449.82%

Índices de Previsibilidade

Receita Líquida

F0.62

Lucro

D0.58

Margem

E1.12

Índices de Tendência

Receita Líquida

B10.26

Lucro

C1.73

Margem

C2.12

Índices de Endividamento

DIV/PAT

1.98

DIV/L4T

-0.44

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.